Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Paraquat Parkinson’s Disease Lawsuits Exposure to the toxic herbicide Paraquat has been linked to a risk of Parkinson's disease.
Gardasil HPV Vaccine Lawsuit Side effects of the Gardasil HPV vaccine have been linked to reports of serious and debilitating autoimmune injuries. Lawyers review cases nationwide.
Omontys Allergic Reaction Problems Appeared Soon After Drug Approved April 2, 2013 Irvin Jackson Add Your Comments Within months after the FDA approved Omontys early last year, troubling adverse event reports about serious and lethal allergic reactions began to surface, which ultimately caused the anemia drug to be recalled from market earlier this year. Omontys (peginesatide) was first released in April 2012 as a joint effort between Takeda Pharmaceuticals and Affymax for treatment of anemia in dialysis patients. According to a recent report by the Wall Street Journal, by August 2012, the FDA was receiving information about severe and sometimes deadly anaphylaxis reactions during a pilot program at Fresenius dialysis centers. Learn More About Omontys Lawsuit An Omontys recall was issued in Feb. 2013 due to risk of allergic reaction, deaths. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Omontys Lawsuit An Omontys recall was issued in Feb. 2013 due to risk of allergic reaction, deaths. Learn More SEE IF YOU QUALIFY FOR COMPENSATION An Omontys recall was issued by February 2013, after it was determined that the potential risks outweighed the benefits. About 25,000 patients were treated with the Omontys before it was removed from the market, most of which received the anemia drugs during treatment at Fresenius dialysis centers. At least 98 adverse event reports were received by the FDA between the release of Omontys and the recall. Information about the Omontys allergic reaction problems reported to the FDA were revealed through Freedom of Information Act requests, highlighting for the first time how quickly the side effect began to emerge. There were at least 12 deaths among Omontys patients where the drug may have been a factor, but the causes of death were not specified. The drug makers said they looked at five deaths before making the decision to recall the drug. At the time of the recall, only three deaths were disclosed, and 19 cases of serious side effects. It appears that the drug makers were aware there was a risk of serious problems with Omontys by fall 2012. Affymax officials say they contacted the FDA about adding an updated warning label to the drug once the adverse event reports began to come in. Allergic reactions on Omontys appeared to occur within 30 minutes of the first injection, which is designed to be given once per month. According to Affymax and Takeda, the reactions occurred in about 0.2% of cases, with about a third of those being serious and sometimes including anaphylaxis that requires prompt medical intervention and hospitalization. Fatal reactions occur in about 0.02% of all cases, according to the manufacturers. Affymax Inc.’s share prices tumbled after the recall and the company announced in a press release last month that  is considering bankruptcy after laying off 75% of its workforce late last month, including its chief commercial officer. The company says the downsizing was so that it could focus on an ongoing investigation into whether Omontys was still a usable product. Tags: Affymax, Allergic Reaction, Anemia, Dialysis, Fresenius, Omontys, Takeda Pharmaceuticals More Omontys Lawsuit Stories Omontys Problems Likely Signal End for Drug Maker: Analysts November 15, 2013 Recalled Omontys Side Effects Now Linked to 22 Deaths October 18, 2013 Omontys Recall Issued Due to Deaths, Anaphylaxis Reactions February 25, 2013 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (Posted: today) A federal judge has outlined the schedule for preparing a group of hair relaxer lawsuits for early bellwether trials, which will not go before a jury until at least 2027. MORE ABOUT: HAIR RELAXER LAWSUITSynthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)Hair Relaxer Wrongful Death Lawsuit Links Fatal Endometrial Cancer to Chemical Straightener Use (03/04/2025)Hair Relaxer Lawsuit Settlement Talks Begin With Focus on Finding Mediator, Parties Report (02/11/2025) Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (Posted: yesterday) A BioZorb tissue marker lawsuit representing five women from across the country claims that the recalled implant was defectively designed, resulting in a recall and numerous complications. MORE ABOUT: BIOZORB LAWSUITBioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025)Judge Indicates BioZorb Recall and Warning Letter Do Not Warrant Reopening Discovery in Bellwether Cases (02/12/2025) Suboxone Lawyers Report on Status of Lawsuits Over Tooth Decay, Dental Damage (Posted: 2 days ago) Suboxone lawyers will meet today with a federal judge, to discuss the status of thousands of tooth decay lawsuits brought over the opioid treatment film strips. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUITMedical Records of Suboxone Tooth Decay Must Be Produced Under MDL Court Order (02/20/2025)Lawyers in Suboxone Dental Lawsuits Fail To Reach Agreement on Bellwether Selection Process (02/06/2025)Another Influx of Suboxone Tooth Decay Lawsuits Expected in Coming Months (01/20/2025)
Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (Posted: today) A federal judge has outlined the schedule for preparing a group of hair relaxer lawsuits for early bellwether trials, which will not go before a jury until at least 2027. MORE ABOUT: HAIR RELAXER LAWSUITSynthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)Hair Relaxer Wrongful Death Lawsuit Links Fatal Endometrial Cancer to Chemical Straightener Use (03/04/2025)Hair Relaxer Lawsuit Settlement Talks Begin With Focus on Finding Mediator, Parties Report (02/11/2025)
Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (Posted: yesterday) A BioZorb tissue marker lawsuit representing five women from across the country claims that the recalled implant was defectively designed, resulting in a recall and numerous complications. MORE ABOUT: BIOZORB LAWSUITBioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025)Judge Indicates BioZorb Recall and Warning Letter Do Not Warrant Reopening Discovery in Bellwether Cases (02/12/2025)
Suboxone Lawyers Report on Status of Lawsuits Over Tooth Decay, Dental Damage (Posted: 2 days ago) Suboxone lawyers will meet today with a federal judge, to discuss the status of thousands of tooth decay lawsuits brought over the opioid treatment film strips. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUITMedical Records of Suboxone Tooth Decay Must Be Produced Under MDL Court Order (02/20/2025)Lawyers in Suboxone Dental Lawsuits Fail To Reach Agreement on Bellwether Selection Process (02/06/2025)Another Influx of Suboxone Tooth Decay Lawsuits Expected in Coming Months (01/20/2025)